REVIEW

Recent advances in understanding chemotherapy-induced peripheral neuropathy [version 1; peer review: 2 approved]

Richard Gordon-Williams , Paul Farquhar-Smith

Department of Pain Medicine, The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK

V1 First published: 11 Mar 2020, 9(F1000 Faculty Rev):177
<https://doi.org/10.12688/f1000research.21625.1>

Latest published: 11 Mar 2020, 9(F1000 Faculty Rev):177
<https://doi.org/10.12688/f1000research.21625.1>

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN.

Keywords

Chemotherapy, Neuropathy, Pain, Survivorship

Open Peer Review

Approval Status

	1	2
version 1 11 Mar 2020

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Irina Vetter**, University of Queensland, Saint Lucia, Australia

2. **Peter M. Grace**, University of Texas MD Anderson Cancer Center, Houston, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Richard Gordon-Williams (r.gordon-williams@nhs.net)

Author roles: **Gordon-Williams R:** Writing – Original Draft Preparation, Writing – Review & Editing; **Farquhar-Smith P:** Conceptualization, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Gordon-Williams R and Farquhar-Smith P. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Gordon-Williams R and Farquhar-Smith P. **Recent advances in understanding chemotherapy-induced peripheral neuropathy [version 1; peer review: 2 approved]** F1000Research 2020, 9(F1000 Faculty Rev):177 <https://doi.org/10.12688/f1000research.21625.1>

First published: 11 Mar 2020, 9(F1000 Faculty Rev):177 <https://doi.org/10.12688/f1000research.21625.1>

Introduction

The last decade has heralded improvements in cancer survival¹. However, persistent effects following the treatment of cancer can lead to pain and an impaired quality of life long after treatment has finished or cancer has been cured². Chemotherapy-induced peripheral neuropathy (CIPN) is one of those effects that can lead to a continuing symptom burden after treatment³.

CIPN is characterised by the classic “glove and stocking” distribution of symptoms. After chemotherapy, 68% of patients have painful neuropathy at 6 months, improving to 33% at 1 year⁴. Although different chemotherapies have variable characteristics, symptoms tend to be predominantly sensory. Sensory toxicity is the predominant feature as dorsal root ganglion (DRG), containing the sensory cell bodies, have a fenestrated endothelium that is more permeable than that found in the spinal cord, where the motor cell bodies lie. Sensory features are characterised by so-called “positive” and “negative” symptoms. “Negative” symptoms include numbness, loss of vibration sense, proprioception and deep tendon reflexes, whereas paraesthesia, dysaesthesia, and cold and mechanical hypersensitivity are referred to as “positive” symptoms.

The development of pain is also a common reason for dose reduction^{4,5}, which may have implications for oncological outcome⁶. The situation is further complicated by the effect of “coasting”, whereby the development of pain is delayed until after stopping the chemotherapy.

Despite advances in cancer treatment and survival, we still have much to learn about CIPN. It is important to recognise that CIPN is a heterogeneous population; it may be acute, such as the neuropathy commonly experienced with oxaliplatin, or chronic, lasting well beyond the end of treatment. Although there may be some overlap in features, it is likely that the underlying pathophysiology, clinical features and therefore its management differ substantially. Furthermore, not all CIPN is considered painful. This review will focus on the mechanisms but also deliberate on clinical features and treatment of chronic painful CIPN.

Animal models

Animal models of CIPN have increased understanding of the pathophysiology of CIPN, yet a recent meta-analysis highlights problems with the current models and may help deliver more robust and valid models⁷. For example, how do studies assessing short-term pain behaviours in animals without tumour burden model chronic CIPN? Pre-clinical studies often focus on the gain-of-function symptoms rather than the loss of function (for example, numbness) more common with chronic CIPN. Misrepresentation of the sexes is evident; 83% of animals used were male. Newer models have addressed some of these criticisms. Griffiths *et al.* describe a paclitaxel model of CIPN for 28 days with ethologically relevant behavioural tests that better mirror the clinical picture⁸. Non-human primate models may be more similar to the human condition⁹ but, owing to ethical and pragmatic issues, are not a feasible alternative to rodents.

Mechanisms

The main classes of chemotherapeutics that cause neuropathy include the platinum-based anti-cancer therapies (oxaliplatin and cisplatin), vinca alkaloids (vincristine and vinblastine), taxanes (paclitaxel and docetaxel), proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). These classes have differing anti-neoplastic mechanisms and likely different mechanisms for neuropathy. Evidence suggests that a number of mechanisms are shared between classes of chemotherapeutics, and most studies investigate the taxanes and the platinum. Currently, these mechanisms can be broadly separated into mitochondrial dysfunction and oxidative stress, microtubule disruption, neuroinflammation and immunological processes, and ion channel dysregulation.

Mitochondrial and oxidative stress

Bioenergetic pathways, predominantly via the oxidation of glucose through the Krebs cycle within the mitochondria, are responsible for the generation of ATP. Chemotherapeutics commonly target nucleolar DNA and may also affect mitochondrial DNA. Indeed, targeting mitochondrial DNA as a principal therapy is an area of ongoing research¹⁰. Whereas nucleolar DNA has well-established repair mechanisms, mitochondria do not. Flatters and Bennett showed that paclitaxel treatment in rats led to swollen vacuolated mitochondria that followed the course of pain-like behaviours for almost 3 months¹¹. Mitochondrial dysfunction within sensory neurones has also been demonstrated by other chemotherapeutics^{12–15}. Krukowski *et al.* found that cisplatin-induced mechanical allodynia is associated with mitochondrial damage in DRG but that the loss of intra-epidermal nerve fibres (IENFs), seen in patients with CIPN, is related to bioenergetic deficits in peripheral nerves¹⁶. Gregg *et al.* found that post-mortem platinum concentrations in patients who received platinum chemotherapy were highest in DRGs and demonstrated a linear relationship between DRG levels and cumulative dose¹⁷, and levels were higher in patients with neuropathy. Animal data suggest a dose-dependent accumulation within the mitochondria of DRG neurones¹⁸. Recently, gene expression analysis further supported mitochondrial dysfunction in patients who develop CIPN. Kober *et al.*¹⁹ found that breast cancer patients who develop neuropathy after paclitaxel demonstrate differential expression in a number of pathways implicated in mitochondrial dysfunction, including oxidative stress²⁰. Additionally, genetic polymorphisms in anti-oxidant pathways have been associated with an increased incidence of CIPN²¹.

Numerous animal studies indicate that chemotherapy worsens oxidative stress^{22,23}. Furthermore, anti-oxidants prevent the development of mitochondrial dysfunction, IENF loss and pain-like behaviours in animal models^{24,25}.

The anti-oxidant alpha-lipoic acid reduces neuropathy in patients with diabetes and also animal models of CIPN²⁶. Concurrent administration of alpha-lipoic acid reduces neuropathic symptoms secondary to bortezomib with less alteration to chemotherapy regimen secondary to adverse events²⁷. However, despite the neuroprotective effects of anti-oxidants

in vitro studies²⁸, there is little clinical evidence for other nutraceutical anti-oxidants in the prevention of CIPN²⁹. Recently, however, a phase I trial showed that calmagafodipir, a manganese superoxide dismutase mimic that aids reactive oxygen species (ROS) degradation, reduces acute and chronic CIPN after oxaliplatin in patients³⁰ without affecting response to chemotherapy and life expectancy. Metformin can also reduce neuropathic behaviours via a reduction in oxidative stress^{13,31,32}. Metformin treatment in 40 patients receiving oxaliplatin reduced National Cancer Institute–Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade 2 and 3 neuropathy with a moderate reduction in neurotoxicity score and a modest reduction in pain³³.

Mitochondria play a key role not only in ROS regulation but in numerous other cellular processes, including calcium buffering, apoptosis and energy production via oxidative phosphorylation. Duggett *et al.* have shown that whereas basal respiration and ATP turnover were unaffected in DRG mitochondria of paclitaxel treated rats, maximal respiration and spare reserve capacity were greatly reduced at peak pain behaviour¹². This indicates a reduced ability of these neurones to respond to stress, and the authors postulated that a switch to glycolysis could be an adaptive mechanism to reduce harmful ROS production.

Schwann cells play a crucial role in the regrowth of peripheral axons after injury; however, Nishida *et al.* found that accumulation of platinum compounds within Schwann cells was much lower than that in peripheral nerves and DRG¹⁸. Conversely, Imai *et al.* suggested that *in vitro* platinum compounds cause mitochondrial dysfunction in Schwann cells at drug concentrations lower than those required to induce neurotoxicity³⁴, suggesting a greater role for mitochondrial dysfunction in Schwann cells in CIPN.

In animal models, treatment with pifithrin- μ , a molecule that suppresses mitochondrial damage, improves mitochondrial morphology, bioenergetics and IENF density while reducing pain behaviours^{14,35}. Combined with evidence that it may act synergistically with the anti-cancer mechanisms of chemotherapeutics^{35,36}, pifithrin- μ represents an exciting prospect in cancer care.

Glia and neuroinflammation

Glia are key in maintaining homeostasis and immunity in the central nervous system in both health and disease. In models of non-chemotherapy-induced neuropathy, microglia have been found to play an integral role in the development of the pain state^{37,38}. Oxaliplatin-treated rats displayed persistent mechanical allodynia, sensory deficits and decreased density of IENFs³⁹. Hu *et al.* showed a persistent activation of spinal cord microglia through strengthening of triggering receptor expressed on myeloid cells 2 (TREM2) signalling and demonstrated that either inhibiting microglia with minocycline or interrupting TREM2 signalling improved pain-like behaviours and IENF density⁴⁰. Furthermore, an agonist at the CB2 cannabinoid receptor, colocalised with spinal microglia,

inhibited microgliosis and pain behaviours in an animal model of paclitaxel-induced neuropathy⁴¹.

Despite these findings, astrogliosis rather than microgliosis is thought to be of greater importance to the development of CIPN^{42,43}, while in some models, astrocyte inhibition with minocycline prevented the development of pain-like behaviours. But how would astrocyte activation lead to the development of CIPN? One proposed mechanism in a rat model of oxaliplatin-induced painful neuropathy is dysregulation of spinal adenosine kinase expression in astrocytes⁴⁴. This may lead to activation of NLRP3/interleukin 1 beta (NLRP3/IL1 β) pathway, promoting dorsal horn neuronal excitability with concurrent suppression of the anti-inflammatory IL-10 system, leading to central sensitisation and pain behaviours^{44,45}. Importantly, restoration of adenosine signalling with an A3AR adenosine receptor agonist prevents the development of both astrogliosis and pain behaviours⁴⁵. Another mechanism proposed in rodent models is through the alteration of sphingolipid signalling within astrocytes in the superficial layers of the dorsal horn of the spinal cord, an area concerned with nociceptive transmission^{46,47}. Maladapted sphingolipid metabolism, through direct bortezomib effects and increased IL-1 β , may increase glutamatergic transmission and consequently nociceptive transmission and pain behaviours⁴⁷.

Reasons for the discrepancies in the role glia play in CIPN remain unclear but the discrepancies may be due to variations in chemotherapy, species, time point and sex studied. Pain phenotype differs greatly between male and female patients, and the pathophysiology in animal models is also sex-dependent⁴⁸. In animal models of bortezomib-induced peripheral neuropathy, modulation of sphingolipid signalling attenuates pain behaviours in male but not female rodents⁴⁷. Additional examples of sexual dimorphism are found in paclitaxel-induced peripheral neuropathy, and Toll-like receptor 9 (TLR9) expression in macrophages infiltrating DRG plays a role in the development of pathophysiological changes and behaviours in male mice but not females⁴⁹. Macrophage infiltration into DRG and peripheral nerves has been seen in a number of animal models of CIPN, and as with other models of neuropathic pain, activation of TLR4 seems to be crucial^{50–52}.

Clinically, minocycline treatment reduced only the acute pain syndrome associated with paclitaxel infusion but not the development of chronic CIPN⁵³. Additionally, in another phase 2 trial, minocycline failed to prevent oxaliplatin-induced peripheral neuropathy⁵⁴. Despite previous pre-clinical trials indicating minocycline's efficacy at inhibiting astrocyte activation and pain behaviours, its actions have been ascribed predominantly to inhibition of microglia and not astrocytes^{55,56}. Given the differential role that microglia may have in CIPN, minocycline's lack of clinical efficacy may be of no surprise and neuroinflammation still represents a worthy area for continued research in the prevention of CIPN. Fingolimod, a drug used in the treatment of multiple sclerosis, downregulates the S1PR1 receptor found on astrocytes. Antagonism of this receptor has been shown to reverse immunochemical and behavioural changes

in rodent models⁴⁷. This presents the exciting prospect of a potentially new mechanistic target with a readily available therapeutic agent; however, additional trials are required to assess both its effects on CIPN and importantly tumour activity.

Ion channels

Pre-clinical studies have highlighted many chemotherapy-induced changes in ion channel expression, possibly driving behavioural changes in other neuropathic pain states⁵⁷.

Changes in sodium channel expression and their sensitisation increase spontaneous neuronal firing and decrease activation threshold⁵⁸, mechanisms possibly analogous to the allodynia, hyperalgesia and paroxysmal sensations of CIPN. In patients, sodium channel dysfunction is found in acute oxaliplatin toxicity⁵⁹, and sodium channel polymorphisms may have a causal role in the development of acute and possibly chronic CIPN⁶⁰. Furthermore, Na_v1.7 channel has been found to be similarly upregulated in nociceptive neurones in both a rat model and patients with chronic paclitaxel-induced peripheral neuropathy⁶¹. Although dysregulation of other sodium channels is seen in pre-clinical studies of CIPN⁶², the clinical efficacy of sodium channel blockers has been disappointing⁶³.

Potassium channel dysregulation is present in animal models of CIPN⁶⁴. Acutely, oxaliplatin leads to the down-regulation of potassium channels in animal models⁶², and Poupon *et al.* found that treatment with a riluzole (a potassium channel activator) prevents the development of persistent CIPN in mice⁶⁵. A phase 2 randomised controlled trial (RCT) investigating the efficacy of riluzole in the prevention of CIPN is under way⁶⁶. Transient receptor potential (TRP) channels are critical in temperature transduction. Oxaliplatin treatment leads to an increased expression of TRPA1, TRPV1 and TRPM8 in sensory neurones⁶⁷. Interestingly, suppression of TREK-1 and TRAAK potassium channels (and an increase in pro-excitatory Na_v1.8 and HCN ion channels) is found on neurones expressing TRPM8, a receptor responsive to cold⁶². This may present a mechanism through which menthol provides symptomatic relief and oxaliplatin produces cold hypersensitivity acutely.

Although calcium channel modulation has shown promise in animal models of CIPN^{68,69}, no direct calcium channel blockers are in clinical use for neuropathic pain. Cisplatin causes an increase in the calcium channel alpha-2-delta subunit, the target of gabapentinoids⁷⁰, and both topical and systemic treatment with gabapentinoids have been found to be beneficial in rat models of CIPN^{71,72}. Despite this, treatment with pregabalin for 3 days before and after each cycle of oxaliplatin failed to prevent CIPN in patients⁷³.

Clinical features

Risk factors

There are many potential predictors in the development of CIPN, including patient-related factors, such as increased age, pre-existing neuropathy, smoking status, and impaired renal function, and chemotherapy-related factors, such as type of chemotherapy, cumulative chemotherapy dose, concurrent chemotherapy treatment, and duration of infusion^{74–76}. Certain cancers may cause a subclinical neuropathy which may predispose patients to CIPN and worsen outcomes⁷⁷.

Genetic markers have been implicated in chemotherapy-related toxicity, and a number of genome-wide association studies have looked at polymorphisms associated with CIPN. A number of polymorphisms have been identified, none of which (at present) has sufficient prognostic value to be of use in the clinical context⁷⁸. Argyriou *et al.*⁷⁸ called for improved methodology and more standardised diagnostic and severity grading to better inform future studies.

Assessment of CIPN

Despite challenges in prevention and treatment, assessment for CIPN should occur before, during and after chemotherapy. Assessment should include (1) diagnosis (including possible differential diagnoses), (2) severity (including functional impairment) and (3) time course of symptoms and relationship to chemotherapy.

Diagnosis of CIPN requires a full history and examination (Table 1). Within the history, it is important to determine

Table 1. Key elements in history and examination.

History	Examination
<ul style="list-style-type: none"> Details of chemotherapy regimen Number of cycles, dose and cumulative dose Onset of symptoms in relation to chemotherapy “Coasting” assessment (neuropathy occurring or worsening after chemotherapy cessation) Evidence of change over time (better or worse) 	Sensation <ul style="list-style-type: none"> Light touch Pinprick or painful stimulus Vibration sense Cold/hot sensation
Symptoms <ul style="list-style-type: none"> Distribution (hands, feet or more proximal) Numbness, paraesthesia, pain, spontaneous or evoked Motor or sympathetic dysfunction Functionality and interference on activities 	Other <ul style="list-style-type: none"> Deep tendon reflexes Motor power Balance

pre-existing risk factors for neuropathy such as diabetes, vitamin deficiency, alcohol use and previous chemotherapy. Blood tests, including a full blood count, comprehensive metabolic profile, measurement of erythrocyte sedimentation rate, fasting blood glucose, vitamin B₁₂, and thyroid-stimulating hormone levels, should be considered to help rule out other causative or contributory causes for neuropathy.

Painful CIPN is a subset that may benefit from further characterisation with multidimensional pain assessment tools. The McGill Pain Questionnaire (MPQ) and the Brief Pain Inventory (BPI) have been validated for use in cancer pain⁷⁹ and although they both assess sensory aspects, including severity, the BPI also assesses impact on function. Likewise, screening tools may aid in the assessment of neuropathic pain. Two such tools, the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) and Douleur Neuropathique 4 (DN4)^{80,81}, have good sensitivity and specificity in cancer pain but are not validated in CIPN. Furthermore, although chemotherapy is a common treatment for childhood cancers and the subsequent neuropathy may differ in phenotype from that of adults^{82,83}, there are few validated tools for the assessment of CIPN in children. One such score is the paediatric-modified total neuropathy score (ped-mTNS), which has been validated in a small group of children undergoing vincristine or cisplatin chemotherapy for leukaemia⁸⁴; however, the 2008 Pediatric Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (PedIMMPACT) called for the development of reliable and valid tools for use in children⁸⁵.

Numerous tools have been developed for the assessment of CIPN; however, there is notable inter-observer variation between these scales. Clinical rated scales such as the Ajani scale, World Health Organization, Eastern Cooperative Oncology Group neuropathy scale, and NCI-Common Toxicity Criteria (NCI-CTC) have limited assessment of pain⁸⁶ and may not truly reflect the incidence of adverse neuropathy, leading to inappropriate treatment reduction or cessation. Furthermore, clinician-rated neuropathy scales underestimate the severity of CIPN when compared with patient-reported measures⁸⁷. In a recent systematic review, Haryani *et al.* suggested that, owing to their psychometric properties and practicality, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) and total neuropathy score (TNS) (see below) were the most appropriate assessment tools available⁸⁸. Yet other studies are contradictory; this is in line with a recent DELPHI survey which showed there is little consensus amongst clinicians⁸⁹.

Fact/GOG-Ntx was developed for assessing the impact of neuropathy on quality of life after chemotherapy for gynaecological cancer and consists of questions on physical, social, emotional and functional wellbeing with an additional 11-question neurotoxicity subscale. This subscale has been used independently and demonstrates good sensitivity in diagnosis and responsiveness to treatment⁹⁰ and has been validated in other non-gynaecological, non-cisplatin/paclitaxel patients. Further shortening the neurotoxic subscale to four sensory questions

maintains the validity and sensitivity while reducing the burden of patient questions⁹¹.

The Patient Neurotoxicity Questionnaire (PNQ) evaluates sensory, motor and functional components of neuropathy with good sensitivity to change over time and showed improved reporting of CIPN when compared with clinician reporting tools such as the NCI-CTC (see above). Importantly, the PNQ assesses the impact of neuropathy on 22 activities (such as fastening buttons or typing) that are not assessed with other tools, thus representing a more holistic patient-centred assessment of neuropathy.

The TNS is an eight-item score of patient report of neuropathic symptoms, examination findings to pinprick, vibration and deep tendon reflexes and nerve conduction studies (NCSs). A shortened version without the electrophysiological factors has been validated: the TNSc (clinical version of the TNS)⁹²; both have been shown to be more sensitive to CIPN changes than NCI-CTC and comparable in changes to quality-of-life measures⁹³. Importantly, TNS delivers both clinician- and patient-rated components. Quality-of-life measures are commonly not assessed in many CIPN tools. The European Organization of Research and Treatment of Cancer (EORTC), 20-item quality-of-life questionnaire, is sensitive to changes in quality of life secondary to CIPN⁹⁴.

Investigations

There has been a great deal of interest in phenotyping CIPN by using minimally invasive tools such as NCSs, quantitative sensory testing (QST) and IENF density. It seems sensible that underlying mechanisms may translate to differing patterns of neuronal loss and therefore differences in functional deficits, yet in practice this theory is not robust. Traditionally, CIPN has been characterised as a predominant sensory neuropathy affecting large myelinated fibre function, and nerve biopsies from patients with cisplatin- and paclitaxel-induced neuropathy show a loss of large fibres with axonal atrophy and secondary demyelination^{95,96}.

Platinum chemotherapeutics cause neuronal cycle arrest within the DRG and therefore likely cause a neuronopathy (also referred to as ganglionopathy) and anterograde neuronal degeneration. On NCS, this would manifest as non-length-dependent neuropathy affecting both the proximal and distal neurone. In contrast, chemotherapeutics interfering with mitochondrial or microtubule function impair axonal transportation giving a length-dependent axonal polyneuropathy, leading to a die back of intraepidermal nerve fibres. However, owing to poor correlation with clinical symptoms, NCSs cannot be routinely recommended. Furthermore, NCSs assess predominantly large-fibre function, missing small-fibre changes that may occur with painful CIPN.

Owing to its ability to assess large- and small-fibre types, QST may be of use in the phenotyping of neuropathic pain⁹⁷ and therefore has been proposed as a useful tool in CIPN⁹⁸. In patients with paclitaxel-induced peripheral neuropathy, the reduction

in light touch and vibration detection thresholds seen in hands and feet supports the mechanism of paclitaxel causing a distal neuropathy predominantly affecting the large, non-nociceptive neurones⁹⁹. Additionally, some report that thermal detection thresholds and pinprick detection are minimally affected, indicating that small-fibre function is preserved in this group. This is in contrast to findings in patients with vincristine and bortezomib-induced neuropathy, with some studies reporting changes in pinprick perception and warm detection thresholds suggesting small, nociceptive fibre dysfunction in this group of patients^{100,101}.

Pre-existing QST sensory deficits increase the risk of developing CIPN¹⁰²; in some cases, cancer itself may be responsible for QST changes¹⁰³. Although the QST sensory profile may differ between agents^{104,105}, QST profiles for painful and painless CIPN may be similar¹⁰⁶ and changes in QST may occur later than symptoms develop¹⁰⁷. Furthermore, QST requires expertise and time and consequently is not commonly used in routine clinical practice for the evaluation of CIPN.

Skin punch biopsy can inform the diagnosis of small-fibre neuropathies. In CIPN, similar to other small-fibre neuropathies, IENF loss is observed¹⁰⁸. Taking comparative distal thigh and distal leg punch biopsies can help differentiate between a length-dependent neuropathy or a neuronopathy; however, evaluating CIPN using IENF densities has been found to be unreliable; there is a large overlap between different chemotherapeutics, and results conflict with other assessment tools^{109–111}. Furthermore, although punch biopsy can be repeated, it is time-consuming and invasive and IENF density has been found to be a poor correlate of pain¹¹².

Other techniques for assessing neuropathy have yet to be fully validated. Nevertheless, simple bedside measures such as vibration sense, light touch and pinprick have good validity in the measurement of neuropathy¹¹³.

Prevention

Reducing regional perfusion (cryotherapy) may reduce CIPN; cooling gloves and stockings have been shown to reduce the risk of desquamation and nail changes associated with chemotherapy. Of the three published trials, only one showed benefit¹¹⁴. Owing to poorly tolerated treatment or a greater-than-expected control group response, the other studies were negative^{115–117}.

In 2014, the American Society of Clinical Oncology evaluated 42 studies while developing guidelines on the prevention of CIPN⁶³. Owing to a lack of high-quality data, they were unable to make any recommendations and encouraged additional research.

Treatment

Pharmacological

RCT evidence of treatments in CIPN suggested that duloxetine is the only anti-neuropathic agent with evidence of benefit¹¹⁸. Many CIPN RCTs fail to meet the IMMPACT guidelines for

outcome measures in clinical trials^{119,120}. Nevertheless, a recent comparative study showed that venlafaxine and duloxetine reduced pain in established CIPN¹²¹. Careful phenotyping may help, as demonstrated with the improved efficacy of oxcarbazepine in the “irritable nociceptor” subgroup¹²². Phenotyping patients for biological and psychosocial characteristics may give additional insight^{122–125}.

Topical treatments are an attractive option for the management of CIPN. A small non-randomised study of topical menthol in 52 patients showed improved BPI scores¹²⁶, and combination therapy with baclofen, amitriptyline and ketamine showed an improvement on some of the EORTC QLQ-CIPN-20 measures¹²⁷. Topical 8% capsaicin patch application following CIPN has been shown to improve continuous pain, neuropathic pain symptoms, and patient global impression of change¹²⁸. This treatment has also been found to improve IENF density, suggesting underlying disease modification¹²⁸.

There is increasing enthusiasm for the use of cannabinoids in the treatment of many chronic pain states. Agonism at CB1 and CB2 receptors has shown analgesia in rodent models of CIPN^{129–133} but these findings have not translated into evidence of clinical efficacy. One published pilot study of nabiximols (THC:CBD mix) in 15 patients with CIPN¹³⁴ showed no significant improvement in pain, but a 2-point decrease over placebo was seen in five patients classified as “responders”¹³⁴.

Without specific evidence for CIPN, clinicians extrapolate treatments from other neuropathic pain states¹³⁵. Interestingly, strong opioids have some of the best “numbers needed to treat” (NNTs) for neuropathic pain (NNT 4.3, 95% confidence interval 3.4–5.8)¹³⁵. Some clinicians may advocate the use of opioids in CIPN, however with increasing survivorship amongst patients with cancer, the possible benefits of opioids should be continually weighed up against the risk of long-term opioid therapy².

Non-pharmacological

Neuromodulation has shown promise in various neuropathic pain states¹³⁶. A number of case reports indicate that neuromodulation may help refractory CIPN^{137,138}, but RCT data are lacking.

A recent study found that the use of wireless transcutaneous electrical nerve stimulation significantly improved some measures of CIPN, including pain, numbness and tingling¹³⁹. Furthermore, scrambler therapy (a novel transcutaneous neurostimulation technique) has been postulated as a potential treatment¹⁴⁰ but was no more effective than sham therapy in a recent RCT¹⁴¹.

Acupuncture

A Cochrane Review of the efficacy of acupuncture in the treatment of cancer pain showed insufficient evidence of its efficacy¹⁴². Since then, a number of trials of acupuncture in CIPN have demonstrated improvements in several domains^{143–145}. A systematic review concluded that there was insufficient evidence to recommend acupuncture for the treatment of

CIPN¹⁴⁶, although low risk of harm and possible benefit may allow its pragmatic use in painful CIPN.

Physical therapy

Exercise has been shown to improve a number of facets that contribute to morbidity associated with CIPN, including balance and strength^{147,148}, numbness, tingling, and hot and cold sensations¹⁴⁹. One study found that, on analysis of the quality-of-life data, exercise had a moderate effect on pain in patients undergoing chemotherapy; however, this was not limited to CIPN¹⁵⁰.

Psychological therapy

Psychological factors have been shown to play a role in both the initiation and maintenance of a number of chronic pain states¹⁵¹. The activity of duloxetine, via enhancing descending inhibitory pathways, suggests that alteration of mood may play a role. In favour of this viewpoint, a study of 111 patients who received treatment for breast cancer found that pre-existing anxiety and pre-therapy numbness were the only factors to predict CIPN eight months later¹⁵². Knoerl *et al.* found that an eight-week web-based cognitive behavioural programme led to modest improvements in worst pain with no differences in mean pain¹⁵³. It was hypothesised that this would be due to improvements in fatigue, anxiety, sleep-related factors,

or depression; however, a follow-up analysis was unable to substantiate these findings¹⁵⁴.

Future directions

Pre-clinical studies have shown that antagonism of the sigma 1 receptor (present on mitochondrial endoplasmic reticulum) is able to reduce mitochondrial structural changes and pain behaviours that occur in CIPN. A phase II clinical trial found that sigma 1 antagonist treatment during FOLFOX chemotherapy diminished cold hypersensitivity, reduced the dropout rate and allowed a higher cumulative dose of oxaliplatin¹⁵⁵. Although the long-term pain outcomes are not known, this highlights a pathway for potential therapeutics that could improve CIPN.

Summary

Despite an ever-expanding body of literature behind the pathophysiology and treatment of CIPN, new treatment options are still limited, and a proportion of patients continue to have difficulty controlling symptoms causing a significant impact on quality of life. Guided by the pre-clinical literature, novel targets that may help prevent CIPN are beginning to emerge. However, with continual advancements in chemotherapeutic agents with novel mechanisms, it is important that ongoing development of treatments for CIPN continue.

References

- Arnold M, Rutherford MJ, Bardot A, *et al.*: **Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.** *Lancet Oncol.* 2019; 20(11): 1493–505.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Brown M, Farquhar-Smith P: **Pain in cancer survivors; filling in the gaps.** *Br J Anaesth.* 2017; 119(4): 723–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mols F, Beijers T, Vreugdenhil G, *et al.*: **Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.** *Support Care Cancer.* 2014; 22(8): 2261–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Seretny M, Currie GL, Sena ES, *et al.*: **Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.** *Pain.* 2014; 155(12): 2461–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gutiérrez-Gutiérrez G, Sereno M, Miralles A, *et al.*: **Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.** *Clin Transl Oncol.* 2010; 12(2): 81–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bhatnagar B, Gilmore S, Golubeva O, *et al.*: **Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.** *SpringerPlus.* 2014; 3: 366.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Currie GL, Angel-Scott HN, Colvin L, *et al.*: **Animal models of chemotherapy-induced peripheral neuropathy: A machine-assisted systematic review and meta-analysis.** *PLoS Biol.* 2019; 17(5): e3000243.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Griffiths LA, Duggett NA, Pitcher AL, *et al.*: **Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.** *Pain Res Manag.* 2018; 2018: 8217613.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hama A, Natsume T, Ogawa S, *et al.*: **Gaps in Understanding Mechanism and Lack of Treatments: Potential Use of a Nonhuman Primate Model of Oxaliplatin-Induced Neuropathic Pain.** *Pain Res Manag.* 2018; 2018: 1630709.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wisnovsky SP, Wilson JJ, Radford RJ, *et al.*: **Targeting mitochondrial DNA with a platinum-based anticancer agent.** *Chem Biol.* 2013; 20(11): 1323–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Flatters SJL, Bennett GJ: **Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction.** *Pain.* 2006; 122(3): 245–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Duggett NA, Griffiths LA, Flatters SJL: **Paclitaxel-induced painful neuropathy is associated with changes in mitochondrial bioenergetics, glycolysis, and an energy deficit in dorsal root ganglia neurons.** *Pain.* 2017; 158(8): 1499–508.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ludman T, Melemedjian OK: **Bortezomib and metformin oppositely regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy.** *Mol Pain.* 2019; 15: 174480691985004.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Maj MA, Ma J, Krukowski KN, *et al.*: **Inhibition of Mitochondrial p53 Accumulation by PFT-μ Prevents Cisplatin-Induced Peripheral Neuropathy.** *Front Mol Neurosci.* 2017; 10: 108.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Xiao WH, Zheng H, Zheng FY, *et al.*: **Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat.** *Neuroscience.* 2011; 199: 461–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Krukowski K, Ma J, Golonzka O, *et al.*: **HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.** *Pain.* 2017; 158(6): 1126–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gregg RW, Molepo JM, Monpetit VJ, *et al.*: **Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity.** *J Clin Oncol.* 1992; 10(5): 795–803.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nishida K, Takeuchi K, Hosoda A, *et al.*: **Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats.** *Life Sci.* 2018; 207: 516–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kober KM, Olshen A, Conley YP, *et al.*: **Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral**

- neuropathy in breast cancer survivors. *Mol Pain*. 2018; 14: 174480691881646.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Ziegler D, Hanefeld M, Ruhnau KJ, *et al.*: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). *Diabetologia*. 1995; 38(12): 1425–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Katayanagi S, Katsumata K, Mori Y, *et al.*: **GSTP1** as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy. *Oncol Lett*. 2019; 17(3): 2897–2904.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Ma J, Kavelaars A, Dougherty PM, *et al.*: Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. *Cancer*. 2018; 124(11): 2289–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. Shim HS, Bae C, Wang J, *et al.*: Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. *Mol Pain*. 2019; 15: 1744806919840098.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Janes K, Doyle T, Bryant L, *et al.*: Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. *Pain*. 2013; 154(11): 2432–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Jin HW, Flatters SJ, Xiao WH, *et al.*: Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. *Exp Neurol*. 2008; 210(1): 229–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Papanas N, Ziegler D: Efficacy of α -lipoic acid in diabetic neuropathy. *Expert Opin Pharmacother*. 2014; 15(18): 2721–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Maschio M, Zarabla A, Maialetti A, *et al.*: Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α -Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. *Integr Cancer Ther*. 2018; 17(4): 1115–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Popović J, Klajn A, Paunesku T, *et al.*: Neuroprotective Role of Selected Antioxidant Agents in Preventing Cisplatin-Induced Damage of Human Neurons *In Vitro*. *Cell Mol Neurobiol*. 2019; 39(5): 619–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Schloss JM, Colosimo M, Airey C, *et al.*: Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. *Clin Nutr*. 2013; 32(6): 888–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Glimelius B, Manojlovic N, Pfeiffer P, *et al.*: Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmagafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT). *Acta Oncol*. 2018; 57(3): 393–402.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Chakraborty A, Chowdhury S, Bhattacharyya M: Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. *Diabetes Res Clin Pract*. 2011; 93(1): 56–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Hou X, Song J, Li XN, *et al.*: Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. *Biochem Biophys Res Commun*. 2010; 396(2): 199–205.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. El-Fataty BM, Ibrahim OM, Hussien FZ, *et al.*: Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. *Int J Colorectal Dis*. 2018; 33(12): 1675–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Imai S, Koyanagi M, Azimi Z, *et al.*: Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. *Sci Rep*. 2017; 7(1): 5947.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Krukowski K, Nijboer CH, Huo X, *et al.*: Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin- μ . *Pain*. 2015; 156(11): 2184–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. McKeon A, Egan A, Chandanshive J, *et al.*: Novel Improved Synthesis of HSP70 Inhibitor, Pifithrin- μ . *In Vitro Synergy Quantification of Pifithrin- μ Combined with Pt Drugs in Prostate and Colorectal Cancer Cells*. *Molecules*. 2016; 21(7): pii: E949.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 37. Zhao H, Alam A, Chen Q, *et al.*: The role of microglia in the pathobiology of neuropathic pain development: what do we know? *Br J Anaesth*. 2017; 118(4): 504–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Sayo A, Konishi H, Kobayashi M, *et al.*: GPR34 in spinal microglia exacerbates neuropathic pain in mice. *J Neuroinflammation*. 2019; 16(1): 82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Di Cesare Mannelli L, Pacini A, Micheli L, *et al.*: Glial role in oxaliplatin-induced neuropathic pain. *Exp Neurol*. 2014; 261: 22–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Hu LY, Zhou Y, Cui WQ, *et al.*: Triggering receptor expressed on myeloid cells 2 (TREM2) dependent microglial activation promotes cisplatin-induced peripheral neuropathy in mice. *Brain Behav Immun*. 2018; 68: 132–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Wu J, Hocevar M, Bie B, *et al.*: Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats. *J Pain*. 2019; 20(5): 501–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Zhang H, Yoon SY, Zhang H, *et al.*: Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. *J Pain*. 2012; 13(3): 293–303.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Robinson CR, Zhang H, Dougherty PM: Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat. *Neuroscience*. 2014; 274: 308–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. Janes K, Wahlman C, Little JW, *et al.*: Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. *Brain Behav Immun*. 2015; 44: 91–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Wahlman C, Doyle TM, Little JW, *et al.*: Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms. *Pain*. 2018; 159(6): 1025–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Janes K, Little JW, Li C, *et al.*: The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. *J Biol Chem*. 2014; 289(30): 21082–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Stockstill K, Doyle TM, Yan X, *et al.*: Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. *J Exp Med*. 2018; 215(5): 1301–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Mapplebeck JCS, Dalgarno R, Tu Y, *et al.*: Microglial P2X4R-evoked pain hypersensitivity is sexually dimorphic in rats. *Pain*. 2018; 159(9): 1752–1763.
[PubMed Abstract](#)
 49. Luo X, Huh Y, Bang S, *et al.*: Macrophage Toll-like Receptor 9 Contributes to Chemotherapy-Induced Neuropathic Pain in Male Mice. *J Neurosci*. 2019; 39(35): 6848–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Zhang H, Li Y, de Carvalho-Barbosa M, *et al.*: Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. *J Pain*. 2016; 17(7): 775–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Li Y, Zhang H, Zhang H, *et al.*: Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. *J Pain*. 2014; 15(7): 712–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 52. Liu CC, Lu N, Cui Y, *et al.*: Prevention of paclitaxel-induced allodynia by minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. *Mol Pain*. 2010; 6: 76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Pachman DR, Dockter T, Zekan PJ, *et al.*: A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU2214081. *Support Care Cancer*. 2017; 25(11): 3407–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Wang XS, Shi Q, Bhadrakamkar NA, *et al.*: Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. *J Pain Symptom Manage*. 2019; 58(4): 662–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Tikka T, Fiebich BL, Goldsteins G, *et al.*: Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. *J Neurosci*. 2001; 21(8): 2580–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Yrjänheikki J, Tikka T, Keinänen R, *et al.*: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. *Proc Natl Acad Sci U S A*. 1999; 96(23): 13496–500.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 57. Aromolaran KA, Goldstein PA: Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy: cause and effect? *Mol Pain*. 2017; 13: 174480691771469.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Bennett DL, Clark AJ, Huang J, *et al.*: The Role of Voltage-Gated Sodium Channels in Pain Signaling. *Physiol Rev*. 2019; 99(2): 1079–151.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. Heide R, Bostock H, Ventzel L, *et al.*: Axonal excitability changes and acute symptoms of oxaliplatin treatment: *In vivo* evidence for slowed sodium channel inactivation. *Clin Neurophysiol*. 2018; 129(3): 694–706.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Argryriou AA, Cavaletti G, Antonacopoulou A, *et al.*: Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. *Cancer*. 2013; 119(9): 3570–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Li Y, North RY, Rhines LD, *et al.*: DRG Voltage-Gated Sodium Channel 1.7 Is

- Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain.** *J Neurosci.* 2018; 38(5): 1124–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Descoeur J, Pereira V, Pizzoccaro A, *et al.*: Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. *EMBO Mol Med.* 2011; 3(5): 266–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 63. Hershman DL, Lacchetti C, Dworkin RH, *et al.*: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol.* 2014; 32(18): 1941–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Viatchenko-Karpinski V, Ling J, Gu JG: Down-regulation of Kv4.3 channels and a-type K⁺ currents in V2 trigeminal ganglion neurons of rats following oxaliplatin treatment. *Mol Pain.* 2018; 14(14): 1744806917750995.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Poupon L, Lamoine S, Pereira V, *et al.*: Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. *Neuropharmacology.* 2018; 140: 43–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Kerckhove N, Busserolles J, Stanbury T, *et al.*: Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup. *BMJ Open.* 2019; 9(6): e027770.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Chukyo A, Chiba T, Kambe T, *et al.*: Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity. *Neuropeptides.* 2018; 67: 95–101.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Rigo FK, Dalmolin GD, Trevisan G, *et al.*: Effect of ω -conotoxin MVIIA and Ph α 1 β on paclitaxel-induced acute and chronic pain. *Pharmacol Biochem Behav.* 2013; 114–115: 16–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. Flatters SJ, Bennett GJ: Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. *Pain.* 2004; 109(1–2): 150–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Dolphin AC: Calcium channel auxiliary $\alpha_2\delta$ and β subunits: trafficking and one step beyond. *Nat Rev Neurosci.* 2012; 13(8): 542–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Han FY, Kuo A, Nicholson JR, *et al.*: Comparative analgesic efficacy of pregabalin administered according to either a prevention protocol or an intervention protocol in rats with cisplatin-induced peripheral neuropathy. *Clin Exp Pharmacol Physiol.* 2018; 45(10): 1067–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Shahid M, Subhan F, Ahmad N, *et al.*: Efficacy of a topical gabapentin gel in a cisplatin paradigm of chemotherapy-induced peripheral neuropathy. *BMC Pharmacol Toxicol.* 2019; 20(1): 51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. de Andrade DC, Jacobsen Teixeira M, Galhardoni R, *et al.*: Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. *Oncologist.* 2017; 22(10): 1154–e105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. Hershman DL, Tili C, Wright JD, *et al.*: Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. *J Clin Oncol.* 2016; 34(25): 3014–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 75. Uwah AN, Ackler J, Leighton JC Jr, *et al.*: The effect of diabetes on oxaliplatin-induced peripheral neuropathy. *Clin Colorectal Cancer.* 2012; 11(4): 275–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. Vincenzi B, Frezza AM, Schiavon G, *et al.*: Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfex IV. *Support Care Cancer.* 2013; 21(5): 1313–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Argyriou AA, Iconomou G, Kalofonos HP: Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. *Blood.* 2008; 112(5): 1593–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Argyriou AA, Bruna J, Genazzani AA, *et al.*: Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. *Nat Rev Neurol.* 2017; 13(8): 492–504.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Caraceni A, Cherny N, Fainsinger R, *et al.*: Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. *J Pain Symptom Manage.* 2002; 23(3): 239–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 80. Bennett M: The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. *Pain.* 2001; 92(1–2): 147–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Bouhassira D, Attal N, Alchaar H, *et al.*: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). *Pain.* 2005; 114(1–2): 29–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. Sandier SG, Tobin W, Henderson ES: Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. *Neurology.* 1969; 19(4): 367.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Kandula T, Park SB, Cohn RJ, *et al.*: Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. *Cancer Treat Rev.* 2016; 50: 118–28.
[PubMed Abstract](#) | [Publisher Full Text](#)
 84. Lavoie Smith EM, Li L, Hutchinson RJ, *et al.*: Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. *Cancer Nurs.* 2013; 36(5): E49–E60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. McGrath PJ, Walco GA, Turk DC, *et al.*: Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. *J Pain.* 2008; 9(9): 771–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 86. Postma TJ, Heimans JJ, Muller MJ, *et al.*: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. *Ann Oncol.* 1998; 9(7): 739–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 87. Shimozuma K, Ohashi Y, Takeuchi A, *et al.*: Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. *Support Care Cancer.* 2009; 17(12): 1483–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 88. Haryani H, Fetzer SJ, Wu CL, *et al.*: Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review. *Oncol Nurs Forum.* 2017; 44(3): E111–E123.
[PubMed Abstract](#) | [Publisher Full Text](#)
 89. McCrary JM, Goldstein D, Boyle F, *et al.*: Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. *Support Care Cancer.* 2017; 25(11): 3485–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
 90. Calhoun EA, Welshman EE, Chang CH, *et al.*: Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. *Int J Gynecol Cancer.* 2003; 13(6): 741–8.
[PubMed Abstract](#)
 91. Huang HQ, Brady MF, Cella D, *et al.*: Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: A gynecologic oncology group study. *Int J Gynecol Cancer.* 2007; 17(2): 387–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
 92. Cavaletti G, Frigeni B, Lanzani F, *et al.*: The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale. *J Peripher Nerv Syst.* 2007; 12(3): 210–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 93. Cavaletti G, Cornblath DR, Merkies IS, *et al.*: The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. *Ann Oncol.* 2013; 24(2): 454–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 94. Postma TJ, Aaronson NK, Heimans JJ, *et al.*: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. *Eur J Cancer.* 2005; 41(8): 1135–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 95. Thompson SW, Davis LE, Kornfeld M, *et al.*: Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. *Cancer.* 1984; 54(7): 1269–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 96. Rowinsky EK, Chaudhry V, Cornblath DR, *et al.*: Neurotoxicity of Taxol. *J Natl Cancer Inst Monogr.* 1993; (15): 107–15.
[PubMed Abstract](#)
 97. Maier C, Baron R, Tölle TR, *et al.*: Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. *Pain.* 2010; 150(3): 439–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 98. Zhi W, Chen P, Kwon A, *et al.*: Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing. *Breast Cancer Res Treat.* 2019; 178(3): 587–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 99. Dougherty PM, Cata JP, Cordella JV, *et al.*: Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. *Pain.* 2004; 109(1–2): 132–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 100. Cata JP, Weng HR, Burton AW, *et al.*: Quantitative sensory findings in patients with bortezomib-induced pain. *J Pain.* 2007; 8(4): 296–306.
[PubMed Abstract](#) | [Publisher Full Text](#)
 101. Dougherty PM, Cata JP, Burton AW, *et al.*: Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. *J Pain Symptom Manage.* 2007; 33(2): 166–79.
[PubMed Abstract](#) | [Publisher Full Text](#)

102. Wang XS, Shi Q, Dougherty PM, *et al.*: **Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.** *Oncology*. 2016; 90(3): 127–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
103. Roldan CJ, Johnson C, Lee SO, *et al.*: **Subclinical Peripheral Neuropathy in Patients with Head and Neck Cancer: A Quantitative Sensory Testing (QST) Study.** *Pain Physician*. 2018; 21(4): E419–E427.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Ventzel L, Madsen CS, Karlsson P, *et al.*: **Chronic Pain and Neuropathy Following Adjuvant Chemotherapy.** *Pain Med*. 2018; 19(9): 1813–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
105. Forstenpointner J, Oberlojer VC, Naleschinski D, *et al.*: **A-Fibers Mediate Cold Hyperalgesia in Patients with Oxaliplatin-Induced Neuropathy.** *Pain Pract*. 2018; 18(6): 758–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
106. Geber C, Breimhorst M, Burbach B, *et al.*: **Pain in chemotherapy-induced neuropathy—more than neuropathic?** *Pain*. 2013; 154(12): 2877–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
107. Delmotte JB, Beaussier H, Auzell N, *et al.*: **Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.** *Cancer Treat Res Commun*. 2018; 17: 31–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
108. Mangus LM, Rao DB, Ebenezer GJ: **Intraepidermal Nerve Fiber Analysis in Human Patients and Animal Models of Peripheral Neuropathy: A Comparative Review.** *Toxicol Pathol*. 2020; 48(1): 59–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
109. Kröigård T, Svendsen TK, Wrenfeldt M, *et al.*: **Early changes in tests of peripheral nerve function during oxaliplatin treatment and their correlation with chemotherapy-induced polyneuropathy symptoms and signs.** *Eur J Neurol*. 2020; 27(1): 68–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
110. Burakgazi AZ, Messersmith W, Vaidya D, *et al.*: **Longitudinal assessment of oxaliplatin-induced neuropathy.** *Neurology*. 2011; 77(10): 980–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
111. Richardson PG, Xie W, Mitsiades C, *et al.*: **Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.** *J Clin Oncol*. 2009; 27(21): 3518–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. Koskinen MJ, Kautio AL, Haanpää ML, *et al.*: **Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy.** *Anticancer Res*. 2011; 31(12): 4413–6.
[PubMed Abstract](#)
113. Griffith KA, Dorsey SG, Renn CL, *et al.*: **Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.** *J Peripher Nerv Syst*. 2014; 19(2): 127–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Hanai A, Ishiguro H, Sozu T, *et al.*: **Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial.** *J Natl Cancer Inst*. 2018; 110(2): 141–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Griffiths C, Kwon N, Beaumont JL, *et al.*: **Cold therapy to prevent paclitaxel-induced peripheral neuropathy.** *Support Care Cancer*. 2018; 26(10): 3461–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
116. Ruddy KJ, Le-Rademacher J, Lacouture ME, *et al.*: **Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511); an ACCRU trial.** *Breast*. 2019; 48: 89–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
117. Sundar R, Bandla A, Tan SS, *et al.*: **Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study.** *Front Oncol*. 2017; 6: 274.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
118. Smith EM, Pang H, Cirrincione C, *et al.*: **Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.** *JAMA*. 2013; 309(13): 1359.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
119. Gewandter JS, Dworkin RH, Finnerup NB, *et al.*: **Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology?** *Pain*. 2017; 158(1): 30–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Dworkin RH, Turk DC, Farrar JT, *et al.*: **Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.** *Pain*. 2005; 113(1–2): 9–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
121. Farshchian N, Alavi A, Heydarheydari S, *et al.*: **Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy.** *Cancer Chemother Pharmacol*. 2018; 82(5): 787–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
122. Demant DT, Lund K, Vollert J, *et al.*: **The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study.** *Pain*. 2014; 155(11): 2263–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
123. Attal N, Rouaud J, Brasseur L, *et al.*: **Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.** *Neurology*. 2004; 62(2): 218–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
124. Finnerup NB, Sindrup SH, Bach FW, *et al.*: **Lamotrigine in spinal cord injury pain: a randomized controlled trial.** *Pain*. 2002; 96(3): 375–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
125. Mainka T, Malewicz NM, Baron R, *et al.*: **Presence of hyperalgesia predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain.** *Eur J Pain*. 2016; 20(1): 116–29.
[PubMed Abstract](#) | [Publisher Full Text](#)
126. Fallon MT, Storey DJ, Krishan A, *et al.*: **Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist.** *Support Care Cancer*. 2015; 23(9): 2769–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
127. Barton DL, Wos EJ, Qin R, *et al.*: **A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.** *Support Care Cancer*. 2011; 19(6): 833–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
128. Anand P, Elsafa E, Privitera R, *et al.*: **Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification.** *J Pain Res*. 2019; 12: 2039–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
129. Mulpuri Y, Marty VN, Munier JJ, *et al.*: **Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.** *Neuropharmacology*. 2018; 139: 85–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
130. Brennehan DE, Kinney WA, Ward SJ: **Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity.** *J Mol Neurosci*. 2019; 68(4): 603–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
131. Sierra S, Gupta A, Gomes I, *et al.*: **Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain.** *ACS Pharmacol Transl Sci*. 2019; 2(4): 219–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
132. King KM, Myers AM, Soroka-Monzo AJ, *et al.*: **Single and combined effects of Δ⁹-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain.** *Br J Pharmacol*. 2017; 174(17): 2832–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
133. Blanton HL, Brelfoard J, DeTurk N, *et al.*: **Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.** *Drugs*. 2019; 79(9): 969–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
134. Lynch ME, Cesar-Rittenberg P, Hohmann AG: **A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.** *J Pain Symptom Manage*. 2014; 47(1): 166–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
135. Finnerup NB, Attal N, Haroutounian S, *et al.*: **Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.** *Lancet Neurol*. 2015; 14(2): 162–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
136. Hofmeister M, Memedovich A, Brown S, *et al.*: **Effectiveness of Neurostimulation Technologies for the Management of Chronic Pain: A Systematic Review.** *Neuromodulation*. 2020; 23(2): 150–157.
[PubMed Abstract](#) | [Publisher Full Text](#)
137. Groenen PS, van Helmond N, Chapman KB: **Chemotherapy-Induced Peripheral Neuropathy Treated with Dorsal Root Ganglion Stimulation.** *Pain Med*. 2019; 20(4): 857–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
138. Abd-Elseyed A, Schiavoni N, Sachdeva H: **Efficacy of spinal cord stimulators in treating peripheral neuropathy: a case series.** *J Clin Anesth*. 2016; 28: 74–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
139. Gewandter JS, Chaudari J, Ibegbu C, *et al.*: **Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.** *Support Care Cancer*. 2019; 27(5): 1765–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
140. Loprinzi C, Le-Rademacher JG, Majithia N, *et al.*: **Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial.** *Support Care Cancer*. 2020; 28(3): 1183–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
141. Smith TJ, Razzak AR, Blackford AL, *et al.*: **A Pilot Randomized Sham-Controlled Trial of MCS-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN).** *J Palliat Care*. 2020; 35(1): 53–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
142. Paley CA, Johnson MI, Tashani OA, *et al.*: **Acupuncture for cancer pain in adults.** *Cochrane Database Syst Rev*. 2015; (10): CD007753.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
143. Jeong YJ, Kwak MA, Seo JC, *et al.*: **Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Trial.** *Evid Based Complement Alternat Med*. 2018; 2018: 1–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

144. Zhi WJ, Ingram E, Li SQ, *et al.*: **Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.** *Integr Cancer Ther.* 2018; **17**(4): 1079–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
145. Molassiotis A, Suen LKP, Cheng HL, *et al.*: **A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy.** *Integr Cancer Ther.* 2019; **18**: 1534735419836501.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
146. Li K, Giustini D, Seely D: **A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy.** *Curr Oncol.* 2019; **26**(2): e147–e154.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
147. Zimmer P, Trebing S, Timmers-Trebing U, *et al.*: **Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial.** *Support Care Cancer.* 2018; **26**(2): 615–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
148. Duregon F, Vendramin B, Bullo V, *et al.*: **Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: A systematic review.** *Crit Rev Oncol Hematol.* 2018; **121**: 90–100.
[PubMed Abstract](#) | [Publisher Full Text](#)
149. Kleckner IR, Kamen C, Gewandter JS, *et al.*: **Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.** *Support Care Cancer.* 2018; **26**(4): 1019–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
150. van Waart H, Stuiver MM, van Harten WH, *et al.*: **Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial.** *J Clin Oncol.* 2015; **33**(17): 1918–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
151. Mundal I, Gråwe RW, Bjørngaard JH, *et al.*: **Psychosocial factors and risk of chronic widespread pain: an 11-year follow-up study--the HUNT study.** *Pain.* 2014; **155**(8): 1555–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
152. Lee KM, Jung D, Hwang H, *et al.*: **Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.** *J Psychosom Res.* 2018; **108**: 14–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
153. Knoerl R, Smith EML, Barton DL, *et al.*: **Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Multicenter, Pilot, Randomized, Wait-List Controlled Trial.** *J Pain.* 2018; **19**(4): 382–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
154. Knoerl R, Barton DL, Holden JE, *et al.*: **Potential mediators of improvement in painful chemotherapy-induced peripheral neuropathy via a web-based cognitive behavioural intervention.** *Can Oncol Nurs J.* 2018; **28**(3): 178–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
155. Bruna J, Videla S, Argyriou AA, *et al.*: **Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.** *Neurotherapeutics.* 2018; **15**(1): 178–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Peter M. Grace**

Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Competing Interests: No competing interests were disclosed.

2. **Irina Vetter**

Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Saint Lucia, QLD, Australia

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research